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Supplementary Figure 1. Forskolin and PPARδ-agonism induce browning of human 
primary adipocytes 
(a) Forskolin (1 μM) increases the expression of brown adipocyte-associated genes in primary 
human adipocytes (Control n = 5, Forskolin n = 6; two-tailed t-test; UCP1 p = 0.0035, PGC1α 
p = 0.0023, CIDEA p = 0.000048, ACADvl p = 0.00014, CYCS p = 0.000055). (b) PPARδ 
agonist GW0742 induces expression of brown adipocyte-associated genes in primary human 
adipocytes Control n = 5, PPARδ agonist n = 6; two-tailed t-test; UCP1 p = 0.007, PGC1α p = 
0.026, CIDEA p = 0.027, CPT1b p = 0.00018, CYCS p = 0.0017). (c) Mitotracker Green 
staining of mitochondria in human primary adipocytes treated with a PPARδ agonist or 
forskolin (representative images of 3 independent repeats; scale bars = 100 μm). (d) Forskolin 
and PPARδ agonism increase mitochondrial content of human primary adipocytes (n = 3; One-
way ANOVA with Dunnett’s post hoc; PPARδ agonist p = 0.0021, Forskolin p < 0.0001). (e) 
Immunohistochemical staining of UCP1 (red) in human primary adipocytes treated with 
forskolin or PPARδ agonist GW0742 (representative images of 3 independent repeats; scale 
bars = 100 μm). (f) Forskolin and PPARδ agonism increase UCP1 protein content in human 
primary adipocytes (n = 3; One-way ANOVA with Dunnett’s post hoc; PPARδ agonist p = 
0.029, Forskolin p = 0.024). (g) Glucose uptake measured using fluorescent 6-NBDG in 
human primary adipocytes treated with forskolin or a PPARδ agoinst (n = 3; One-way ANOVA 
with Dunnett’s post hoc; Forskolin p < 0.0015). (h) Extracellular glycerol as a measure of 
lipolysis analyzed using gas chromatography-mass spectrometry from the media of forskolin 
and PPARδ agonist treated human primary adipocytes (n = 3; One-way ANOVA with Dunnett’s 
post hoc; PPARδ agonist p = 0.009, Forskolin p = 0.0024). Blue = PPARδ agonist, Red = 
Forskolin. ∗p ≤ 0.05, ^p ≤ 0.01, •p ≤ 0.001, ‡p ≤ 0.0001. Data are mean ± SEM with data points 
shown. Source data are provided as a Source Data file. 
   
  
 
Supplementary Figure 2. Metabolites secreted from browning human primary 
adipocytes induce a brown adipocyte-like phenotype 
UCP1 expression in primary human adipocytes treated with (a) 3-methyl-2-oxovaleric acid 
(MOVA; 10 μM, 20 μM, 40 μM; n = 3; One-way ANOVA with Dunnett’s post hoc; 20 μM p = 
0.015, 40 μM p = 0.0026), (b) 5-oxoproline (5OP; 10 μM, 20 μM, 40 μM; n = 3; One-way 
ANOVA with Dunnett’s post hoc; 20 μM p = 0.012, 40 μM p = 0.003), (c) β-hydroxyisovaleric 
acid (BHIVA; 5 μM, 10 μM; n = 3; One-way ANOVA with Dunnett’s post hoc; 10 μM p = 0.048) 
and (d) β-hydroxyisobutyric acid (BHIBA; 10 μM, 20 μM, 40 μM; n = 3; One-way ANOVA with 
Dunnett’s post hoc; 40 μM p = 0.028). (e) Schematic showing TCA cycle 13C-enrichment from 
13C-palmitate metabolism in metabokine-treated human adipocytes. Red carbons represent 
13C-labeling. Glucose uptake in (f) MOVA (Control n = 26, 5 μM n = 10, 20 μM n = 29; One-
way ANOVA with Dunnett’s post hoc; 20 μM p = 0.0018), (g) 5OP (Control n = 32, 5 μM n = 
7, 20 μM n = 28; One-way ANOVA with Dunnett’s post hoc; 20 μM p < 0.0001), (h) BHIVA 
(Control n = 35, 2.5 μM n = 9, 10 μM n = 30; One-way ANOVA with Dunnett’s post hoc; 10 μM 
p < 0.0001) and (i) BHIBA (Control n = 24, 5 μM n = 9, 20 μM n = 29; One-way ANOVA with 
Dunnett’s post hoc; 20 μM p = 0.0009) treated human primary adipocytes. Fatty acid uptake 
in (j) MOVA (Control n = 23, 5 μM n = 14, 20 μM n = 18; One-way ANOVA with Dunnett’s post 
hoc; 20 μM p = 0.012), (k) 5OP (Control n = 23, 5 μM n = 43, 20 μM n = 32; One-way ANOVA 
with Dunnett’s post hoc; 20 μM p = 0.023), (l) BHIVA ((Control n = 23, 2.5 μM n = 10, 10 μM 
n = 18; One-way ANOVA with Dunnett’s post hoc; 20 μM p = 0.0002) and (m) BHIBA (Control 
n = 23, 5 μM n = 34, 20 μM n = 18; One-way ANOVA with Dunnett’s post hoc; 20 μM p = 
0.003) treated human primary adipocytes. Mitostress respirometry traces of immortalized 
human white preadipocytes isolated from neck fat and differentiated to mature adipocytes in 
the presence of (n) MOVA (20 μM; Control n = 26, MOVA n = 29), (o) 5OP (20 μM; Control n 
= 29, MOVA n = 28), (p) BHIVA (10 μM; Control n = 28, MOVA n = 30) and (q) BHIBA (20 μM; 
n = 29). Points in the assay at which oligomycin (Oligo), carbonyl cyanide 4-
(trifluoromethoxy)phenylhydrazone (FCCP) and rotenone and antimycin A (Rot/AA) were 
added are shown. Dark green = MOVA, light green = 5OP, purple = BHIVA, dark blue = BHIBA. 
∗p ≤ 0.05, ^p ≤ 0.01, •p ≤ 0.001, ‡p ≤ 0.0001. Bar graphs show mean ± SEM with data points 
shown. Box and whisker plots show 25th to 75th percentile (box) min to max (whiskers), mean 
(+) and median (-). Source data are provided as a Source Data file. 
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Supplementary Figure 3. 13C-isotope substrate tracing and RNA-seq reveal 
mechanisms of MOVA, BHIBA, BHIVA and 5OP biosynthesis in browning human 
adipocytes 
(a) Isoleucine metabolism to 3-methyl-2-oxovaleric acid (MOVA) showing 13C-labeled 
substrates and products. (b) RNA-seq identifies increased expression of branched chain 
amino acid transaminase 2 (BCAT2), which catalyses the reaction producing MOVA, in 
forskolin-treated primary human adipocytes. (c) Intracellular adipocyte 13C-labeled MOVA (n 
= 4; p =0.018) and (d) extracellular 13C-labeled MOVA (n = 4; p = 0.0003) in conditioned media 
from forskolin-treated human primary adipocytes incubated with 13C-labeled isoleucine. (e) 
Valine metabolism to β-hydroxyisobutyric acid (BHIBA) showing 13C-labeled substrates and 
products. RNA-seq of forskolin-treated adipocytes identifies increased expression of BCAT2, 
(f) branched chain keto acid dehydrogenase E1 subunit beta (BCKDHB), (g) acyl-CoA 
dehydrogenase short chain (ACADS), and (h) Enoyl-Coenzyme A, Hydratase/3-Hydroxyacyl 
Coenzyme A Dehydrogenase (EHHADH), hydroxyacyl-CoA dehydrogenase (HADHA) and 
Enoyl-CoA Hydratase, Short Chain 1 (ECHS1), which catalyze the generation of BHIBA from 
valine. (i) Intracellular adipocyte 13C-labeled BHIBA (n = 4; p = 0.0003) and (j) extracellular 
13C-labeled BHIBA (n = 4; p = 0.0039) in conditioned media from forskolin-treated human 
primary adipocytes incubated with 13C-labeled valine. (k) Leucine metabolism to β-
hydroxyisovaleric acid (BHIVA) showing 13C-labeled substrates and products. RNA-seq of 
forskolin-treated adipocytes identifies increased expression of BCAT2, BCKDHB, (l) acyl-CoA 
dehydrogenase medium chain (ACADM), and EHHADH, HADHA and ECHS1, which catalyze 
the generation of BHIVA from valine. (m) Intracellular adipocyte 13C-labeled BHIVA (n = 3; p 
= 0.0101) and (n) extracellular 13C-labeled BHIVA (n = 3; p = 0.031) in conditioned media from 
forskolin-treated human primary adipocytes incubated with 13C-labeled leucine. (o) Glutamate 
metabolism to 5-oxoproline (5OP) showing 13C-labeled substrates and products. Expression 
of the 5OP biosynthetic enzymes (p) glutamate-cysteine ligase catalytic subunit (GCLC), (q) 
glutathione synthetase (GSS), (r) γ-glutamyltransferase 7 (GGT7) and (s) γ-
glutamylcyclotransferase (GGCT) from RNA-seq data of forskolin-treated human primary 
adipocytes. (t) Intracellular adipocyte 13C-labeled 5OP (Control n = 3, 5OP n = 4; p = 0.028) 
and (u) extracellular 13C-labeled 5OP (Control n = 3, 5OP n = 4; p = 0.002) in conditioned 
media from forskolin-treated human primary adipocytes incubated with 13C-labeled 
glutamate. ∗p ≤ 0.05, ^p ≤ 0.01, •p ≤ 0.001. Dark green = MOVA, light green = 5OP, purple = 
BHIVA, dark blue = BHIBA. 13C in structures are labeled in red. Data in bar charts and tables 
was analysed with a two-tailed t-test. Bar charts are mean ± SEM with individual data shown. 
Data in tables are Log fold-change (Log FC) of three biological replicates p-values calculated 
by Exact test. Source data are provided as a Source Data file. 
 
Supplementary Figure 4. Export of metabolite signals from browning adipocytes is 
mediated by monocarboxylate transporters 
The concentration of (a) 3-methyl-2-oxovaleric acid (MOVA) (Extracellular; Control vs 
Forskolin p = 0.035, Forskolin vs MCTi p = 0.029, Forskolin vs Forskolin + MCTi p = 0.03) 
(Intracellular; Control vs Forskolin p = 0.047, Control vs MCTi p = 0.023, Control vs Forskolin 
+ MCTi p = 0.03, Forskolin vs Forskolin + MCTi p = 0.027) (b) 5-oxoproline (5OP) 
(Extracellular; Control vs Forskolin p = 0.028, Forskolin vs MCTi p = 0.012, Forskolin vs 
Forskolin + MCTi p = 0.034) (Intracellular; Control vs Forskolin p = 0.018, Control vs MCTi p 
= 0.032, Control vs Forskolin + MCTi p = 0.0017, Forskolin vs Forskolin + MCTi p = 0.043) (c) 
β-hydroxyisovaleric acid (BHIVA) (Extracellular; Control vs Forskolin p = 0.0003, Forskolin vs 
MCTi p = 0.0045, Forskolin vs Forskolin + MCTi p = 0.036) (Intracellular; Control vs MCTi p = 
0.042, Control vs Forskolin + MCTi p < 0.0001, Forskolin vs Forskolin + MCTi p = 0.003, MCTi 
vs Forskolin + MCTi p = 0.015) and (d) β–hydroxisobutyric acid (BHIBA) (Extracellular; Control 
vs Forskolin p = 0.0023, Forskolin vs MCTi p = 0.0028, Forskolin vs Forskolin + MCTi p = 
0.04) (Intracellular; Control vs Forskolin p = 0.05, Control vs MCTi p = 0.028, Control vs 
Forskolin + MCTi p = 0.001, Forskolin vs Forskolin + MCTi p = 0.048, MCTi vs Forskolin + 
MCTi p = 0.0099) in adipocytes (intracellular) and media (extracellular) of cells treated with 
either forskolin (1 μM), the monocarboxylate transporter inhibitor (MCTi) α-cyano-4-
hydroxycinnamate (2 mM) or both forskolin and α-cyano-4-hydroxycinnamate (n = 4; two-tailed 
t-test). ∗p ≤ 0.05, ^p ≤ 0.01, •p ≤ 0.001, ‡p ≤ 0.0001. Data are mean ± SEM with data points 





Supplementary Figure 5. MOVA, 5OP and BHIBA induce a dose responsive increase in 
oxidative energy metabolism in human primary skeletal myocytes  
The expression of a mitochondrial and metabolic gene panel in human primary skeletal 
myocytes treated with (a) 3-methyl-2-oxovaleric acid (MOVA; 5 μM, 20 μM; n = 4; two-tailed 
t-test; 5 μM ACADvl p = 0.011; 20 μM PPARα p = 0.05, CPT1b p = 0.05, ACADvl p = 0.015), 
(b) 5-oxoproline (5OP; 5 μM, 20 μM; n = 4; two-tailed t-test; 5 μM CPT1b p = 0.005, ACADvl 
p = 0.034; 20 μM PPARα p = 0.03, PGC1α p = 0.05, CPT1b p = 0.018, ACADvl p = 0.016), 
(c) β-hydroxyisobutyric acid (BHIBA; Control n = 3, 5 μM n = 3, 20 μM n = 4; two-tailed t-test; 
20 μM PPARα p = 0.003, CPT1b p = 0.011) (d) β-hydroxyisovaleric acid (BHIVA; 2.5 μM, 10 
μM; n = 4). Basal oxygen consumption in human primary skeletal myocytes treated with (e) 
MOVA (Control n = 21; 5 and 20 μM n = 7; One-way ANOVA with Dunnett’s post hoc; 5 μM p 
= 0.034, 20 μM p = 0.012) (f) 5OP (Control n = 21; 5 μM n = 7 and 20 μM n = 8; One-way 
ANOVA with Dunnett’s post hoc; 20 μM p = 0.0085), (g) BHIBA (Control n = 21; 5 μM n = 6 
and 20 μM n = 8; One-way ANOVA with Dunnett’s post hoc; 5 μM p = 0.03, 20 μM p = 0.0002) 
and (h) BHIVA (Control n = 21; 2.5 μM n = 7 and 10 μM n = 8). Glucose uptake (6-(N-(7-
Nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-6-Deoxyglucose; 6-NBDG) in (i) MOVA (Control n = 
180; 5 μM n = 36 and 20 μM n = 95; One-way ANOVA with Dunnett’s post hoc; 5 μM p = 
0.0014, 20 μM p < 0.0001), (j) 5OP (Control n = 180; 5 μM n = 36 and 20 μM n = 98; One-way 
ANOVA with Dunnett’s post hoc; 5 μM p = 0.02, 20 μM p < 0.0001), (k) BHIBA (Control n = 
180; 5 μM n = 36 and 20 μM n = 106; One-way ANOVA with Dunnett’s post hoc; 20 μM p < 
0.0001) treated human skeletal myocytes. Fatty acid (BODIPY-FA) uptake in (l) MOVA 
(Control n = 272; 5 μM n = 48 and 20 μM n = 144; One-way ANOVA with Dunnett’s post hoc; 
5 μM p = 0.0001, 20 μM p < 0.0001), (m) 5OP (Control n = 272; 5 μM n = 48 and 20 μM n = 
144; One-way ANOVA with Dunnett’s post hoc; 20 μM p = 0.0001), (n) BHIBA (Control n = 
272; 5 μM n = 44 and 20 μM n = 140; One-way ANOVA with Dunnett’s post hoc; 20 μM p = 
0.0001) treated human skeletal myocytes. Dark green = MOVA, light green = 5OP, purple = 
BHIVA, dark blue = BHIBA. ∗p ≤ 0.05, ^p ≤ 0.01, •p ≤ 0.001, ‡p ≤ 0.0001. Data in bar charts 
are mean ± SEM with data points shown. Box and whisker plots show 25th to 75th percentile 




   
  
 
Supplementary Figure 6. Cold exposure induces a thermogenic phenotype and diet-
induced obesity induces whitening to modulate metabokine concentrations in brown 
adipose tissue in mice 
Thermogenic gene expression in the (a) interscapular brown adipose tissue (n = 6; One-Way 
ANOVA with Dunnett’s post hoc; Ucp1 TN vs W p < 0.0001, TN vs M p = 0.008, RT vs W p < 
0.0001, RT vs M p = 0.037; Pgc1α TN vs W p = 0.001, RT vs W p = 0.024; Cidea TN vs W p 
< 0.0001, TN vs M p < 0.0001, RT vs W p < 0.0001, RT vs M p < 0.0001; Cycs TN vs W p < 
0.0001, TN vs M p < 0.0001, RT vs W p < 0.0001, RT vs M p < 0.0001; Cpt1b TN vs W p < 
0.0001, TN vs M p < 0.0001, RT vs W p < 0.0001, RT vs M p < 0.0001, Acadvl TN vs W p < 
0.0001, TN vs M p < 0.0001, RT vs W p < 0.0001, RT vs M p < 0.0001) and (b) subcutaneous 
inguinal adipose tissue (TN, RT n = 6, W, M n = 4; One-Way ANOVA with Dunnett’s post hoc; 
Ucp1 TN vs W p = 0.026, TN vs M p = 0.0005, RT vs W p = 0.026, RT vs M p = 0.0005; Pgc1α 
TN vs M p < 0.0001, RT vs M p < 0.0001, W vs M p = 0.0007; Cidea TN vs W p < 0.0001, TN 
vs M p = 0.0039, RT vs W p < 0.0001, RT vs M p = 0.014; Cycs TN vs M p < 0.0001, RT vs M 
p < 0.0001; Cpt1b TN vs W p < 0.0001, TN vs M p = 0.0008, RT vs W p < 0.0001, RT vs M p 
= 0.0016; Acadvl TN vs W p < 0.0001, TN vs M p < 0.0001, RT vs W p < 0.0001, RT vs M p 
< 0.0001) of mice housed at thermoneutrality (TN), room temperature (RT), 8˚C for 1 week 
(W) or 8˚C for 1 month (M). (c) Immunohistochemical staining of UCP1 protein (red) 
counterstained with hematoxylin in the brown adipose tissue of cold conditioned mice 
(representative images of 6 independent repeats). (d) UCP1 protein is increased in the brown 
adipose tissue of cold conditioned mice (n = 6; One-Way ANOVA with Dunnett’s post hoc; TN 
vs W, p = 0.0064, TN vs M p < 0.0001, RT vs M p = 0.0013). (e) Immunohistochemical staining 
of UCP1 protein (red) counter stained with hematoxylin in the subcutaneous adipose tissue of 
cold conditioned mice (representative images of 5 independent repeats). (f) UCP1 protein is 
increased in the subcutaneous adipose tissue of cold conditioned mice (n = 5; One-Way 
ANOVA with Dunnett’s post hoc; TN vs W, p = 0.043, TN vs M p = 0.0084, RT vs W p = 0.03 
RT vs M p = 0.0057). (g) Weights of mice receiving standard chow (Chow) or 60% fat diet 
(HFD) for 17 weeks (Chow n = 5; HFD n = 9; two-tailed t-test; p < 0.0001). (h) Intraperitoneal 
glucose tolerance test in Chow and HFD-fed mice (Chow n = 5; HFD n = 9; Two-Way ANOVA 
p < 0.0001; two-tailed t-test; 0 min p = 0.006, 30 min p = 0.0009, 60 min p < 0.0001, 90 min p 
= 0.0002). (i) Reduced thermogenic gene expression in the brown adipose tissue of HFD-fed 
mice compared to chow-fed mice n = 5; two-tailed t-test; Pgc1α p = 0.015; Cidea p = 0.019; 
Cpt1b p = 0.011; Acadvl p = 0.011 Cycs p = 0.008). (j) Hematoxylin and eosin stained brown 
adipose tissue from HFD-fed mice demonstrates whitening compared with brown adipose 
tissue from chow-fed mice (representative images of 5 independent repeats). (k) 
Concentrations of 3-methyl-2-oxovaleric acid (MOVA), 5-oxoproline (5OP), β-
hydroxyisovaleric acid (BHIVA) and β-hydroxyisobutyric acid (BHIBA) are lower in brown 
adipose tissue from HFD mice (n = 5; two-tailed t-test; MOVA p = 0.019; 5OP p = 0.028, BHIVA 
p = 0.026, BHIBA p = 0.036). ∗p ≤ 0.05, ^p ≤ 0.01, •p ≤ 0.001, ‡p ≤ 0.0001. Data in bar charts 
are mean ± SEM with data points shown. Box and whisker plots show 25th to 75th percentile 





Supplementary Figure 7. Plasma concentrations of metabolites are inversely correlated 
with BMI in humans (a - d) The inverse correlation of 3-methyl-2-oxovaleric acid (MOVA) (r2 
= 0.2311, p = 0.027), 5-oxoproline (5OP) (r2 = 0.1490, p = 0.084, β-hydroxyisovaleric acid 
(BHIVA) (r2 = 0.2433, p = 0.023) and β-hydroxyisobutyric acid (BHIBA) (r2 =0.2020, p = 0.041) 
plasma concentration to Body Mass Index (BMI) in human volunteers (n = 21). Dark green = 
MOVA, light green = 5OP, purple = BHIVA, dark blue = BHIBA. Analysis by Pearson 
correlation. Source data are provided as a Source Data file. 
  
 
Supplementary Figure 8. Physiological concentrations of MOVA, 5OP and BHIBA 
increase systemic energy expenditure in vivo  
(a - d) The plasma concentration of 3-methyl-2-oxovaleric acid (MOVA; p = 0.0007), 5-
oxoproline (5OP; p = 0.045), β-hydroxyisobutyric acid (BHIBA; p = 0.025) and β-
hydroxyisovaleric acid (BHIVA; p = 0.015) in mice given 100 mg/kg/day MOVA, 100 mg/kg/day 
5OP, 150 mg/kg/day BHIBA and 125 mg/kg/day BHIVA, respectively, in their drinking water 
compared to control mice (n = 5; two-tailed t-test). (e) Water intake in MOVA, 5OP, BHIBA 
and BHIVA-treated mice (n = 5). (f) The weights of mice receiving MOVA, 5OP, BHIBA and 
BHIVA in their drinking water compared to untreated controls (n = 5; two-tailed t-test; MOVA 
p = 0.05, 5OP p = 0.042). Diurnal average energy expenditure for 24 hour period, 12 hour 
dark phase (DARK) and 12 hour light phase (LIGHT) of (g) MOVA (LIGHT p = 0.027) , (h) 
5OP (24 hrs p = 0.041, DARK p = 0.034), (i) BHIBA (24 hrs p = 0.008, LIGHT p = 0.025, DARK 
p = 0.009) and (j) BHIVA treated mice (n = 5; ANCOVA with body mass as a covariate). Diurnal 
average oxygen consumption for 24 hours, 12 hour dark phase (DARK) and 12 hour light 
phase (LIGHT) of (k) MOVA (LIGHT p = 0.05), (l) 5OP (24 hrs p = 0.035, DARK p = 0.031), 
(m) BHIBA (24 hrs p = 0.0066, LIGHT p = 0.024, DARK p = 0.0077) and (n) BHIVA treated 
mice (n = 5; ANOCVA with body mass as a covariate). (o) Activity and (p) food consumption 
of MOVA, 5OP, BHIBA and BHIVA-treated mice (n = 5; two-tailed t-test; food consumption 
5OP p = 0.01, BHIBA p = 0.003). Thermogenic and brown adipocyte-associated gene 
expression in (q) brown adipose tissue (BAT) (n = 5; two-tailed t-test; MOVA Ucp1 p = 0.0006, 
Cidea p = 0.003, Cpt1b p = 0.0007, Acadvl p = 0.00332334, Cycs p = 0.006; 5OP Cidea p = 
0.0005, Cpt1b p < 0.0001, Acadvl p = 0.002, Cycs p = 0.0018; BHIBA Ucp1 p = 0.019, Cidea 
p = 0.0014, Cpt1b p = 0.0005, Acadvl p = 0.025, Cycs p = 0.005; Cold Ucp1 p = 0.003, Cidea 
p = 0.012, Cpt1b p < 0.0001, Acadvl p < 0.0001, Cycs p < 0.0001) and (r) subcutaneous white 
adipose tissue (WAT) (n = 5, Cold Conditioned n = 4; two-tailed t-test; MOVA, PGC1α p = 
0.0017, Cidea p = 0.009, Acadvl p = 0.0014, Cycs p = 0.005; 5OP PGC1α p = 0.0004, Acadvl 
p = 0.0008, Cycs p = 0.0015; BHIBA PGC1α p = 0.0004, Cidea p = 0.02, Acadvl p = 0.0007, 
Cycs p = 0.05; Cold Ucp1 p = 0.0097, PGC1α p = 0.027, Cidea p = 0.006, Cpt1b p = 0.002, 
Acadvl p = 0.00011, Cycs p < 0.0001) of MOVA, 5OP, BHIBA and BHIVA-treated mice. 
Expression of mitochondrial and metabolic genes in the (s) gastrocnemius (MOVA Cpt1b p = 
0.0026, Acadvl p = 0.04, Cycs p = 0.007, Ndufs1 p = 0.02; 5OP Pgc1α p = 0.007, Pparα p = 
0.05, Cpt1b p = 0.02, Cycs p = 0.0028, Ndufs1 p = 0.014; BHIBA Pgc1α p = 0.0019, Cpt1b p 
= 0.0007, Acadvl p = 0.007, Cycs p = 0.02) and (t) soleus muscles (MOVA Ndufs1 p = 0.011; 
5OP Pparα p = 0.034, Cpt1b p = 0.0027, Acadvl p = 0.03; BHIBA Pparα p = 0.0007, Cpt1b p 
= 0.005) of metabokine-treated mice (n = 5; two-tailed t-test). Metabokine treatment increases 
mitochondrial content in (u) BAT (MOVA p = 0.035, BHIBA p = 0.015) (v) subcutaneous WAT 
(MOVA p = 0.038, 5OP p = 0.01, BHIBA p = 0.013) (w) gastrocnemius (MOVA p = 0.046, 5OP 
p = 0.0029) and (x) soleus muscle (MOVA p = 0.012, 5OP p = 0.017, BHIBA p = 0.012) of 
mice, determined using a citrate synthase assay (n = 5; two-tailed t-test). Dark green = MOVA, 
light green = 5OP, purple = BHIVA, dark blue = BHIBA. ∗p ≤ 0.05, ^p ≤ 0.01, •p ≤ 0.001, ‡p ≤ 
0.0001. Data in bar charts are mean ± SEM with data points shown. Source data are provided 
as a Source Data file. 
 
Supplementary Figure 9. The metabolites increase oxygen consumption, improve 
glucose tolerance and induce a phenotype and morphology consistent with browning 
in adipose tissue in obese mice 
(a - c) The plasma concentration of 3-methyl-2-oxovaleric acid (MOVA) (p = 0.012, 5-
oxoproline (5OP) (p = 0.035), and β-hydroxyisobutyric acid (BHIBA) (p = 0.01) in mice given 
100 mg/kg/day MOVA, 100 mg/kg/day 5OP, or 150 mg/kg/day BHIBA, respectively, in their 
drinking water compared to control mice (n = 5; two-tailed t-test). Diurnal average oxygen 
consumption for 24 hour period, 12 hour dark phase (DARK) and 12 hour light phase (LIGHT) 
of (d) MOVA (n = 9; 24 hrs p = 0.001, DARK p = 0.014, LIGHT p = 0.0092) (e) 5OP (n = 9; 24 
hrs p = 0.005, DARK p = 0.032, LIGHT p = 0.005), and (f) BHIBA (n = 8; 24 hrs p = 0.016) 
treated mice fed a 60% fat diet compared to controls (n = 8; ANCOVA with body weight as a 
covariate). (g) Daily activity (beam breaks) (Control, BHIBA n = 8; 5OP, MOVA n = 9), (h) food 
consumption (Control, BHIBA n = 8; 5OP, MOVA n = 9) and (i) water intake (n = 5) of mice 
treated with 100 mg/kg/day MOVA, 100 mg/kg/day 5OP or 150 mg/kg/day BHIBA. (j) Area 
under the curve (AUC) of intraperitoneal insulin tolerance tests of BHIBA, 5OP, or MOVA-
treated mice (n = 10, Control n = 9; two-tailed t-test; BHIBA p = 0.019, 5OP p = 0.043). 
Intraperitoneal glucose tolerance tests of (k) MOVA, (l) 5OP (Two-Way ANOVA p = 0.0006; 
two-tailed t-test, 60 min p = 0.02, 90 min p = 0.05) and (m) BHIBA (Two-Way ANOVA p < 
0.0001; two-tailed t-test, 60 min p = 0.012, 90 min p = 0.03, 120 min p = 0.027) treated mice 
(n = 9). (n) AUC of intraperitoneal glucose tolerance tests of BHIBA (p = 0.024), 5OP (p = 
0.045), or MOVA-treated mice. (n = 9; two-tailed t-test) (o) Immunohistochemical staining of 
Ucp1 protein (red) counterstained with hematoxylin in the brown adipose tissue (top panels) 
and inguinal subcutaneous adipose tissue (bottom panels) of BHIBA, 5OP and MOVA-treated 
mice (representative images of 5 independent repeats). (p) Adipocyte area of the 
subcutaneous adipose tissue of BHIBA (p = 0.046), 5OP (p = 0.008), or MOVA (p = 0.027) 
treated mice with data points shown (n = 5; two-tailed t-test). Dark green = MOVA, light green 
= 5OP, dark blue = BHIBA. ∗p ≤ 0.05, ^p ≤ 0.01, •p ≤ 0.001, ‡p ≤ 0.0001. Data in bar charts 
are mean ± SEM with data points shown. Box and whisker plots show 25th to 75th percentile 






Supplementary Figure 10. The metabolites MOVA and 5OP have additive effects on 
body weight and glucose disposal in high fat diet-fed mice  
(a) The reduction in weight gain in mice given a combination of 3-methyl-2-oxovaleric acid 
(MOVA) and 5-oxoproline (5OP) was greater than either MOVA or 5OP treatments (Control n 
= 9; MOVA, 5OP n = 10; MOVA + 5OP n = 5; Two-way ANOVA with Holm-Sidak post hoc; 
Control vs MOVA + 5OP p < 0.0001; MOVA vs MOVA + 5OP p < 0.0001; 5OP vs 5OP + 
MOVA p < 0.0001). (b) Computed Tomography demonstrates that combined MOVA and 5OP 
treatment significantly reduces adiposity in mice (n = 5; two-tailed t-test; p = 0.007). (c) 
Intraperitoneal glucose tolerance tests showed a greater improvement in glucose tolerance in 
the MOVA and 5OP combination-treated mice (Control; MOVA, 5OP n = 9; MOVA + 5OP n = 
5; Two-Way ANOVA with Holm-Sidak post hoc; 120 min; MOVA vs MOVA + 5OP p = 0.004, 
5OP vs MOVA + 5OP p = 0.046). (d) Positron emission tomography / computed tomography 
(PET/CT) 18F-fluorodeoxyglucose (18F-FDG) imaging of BHIBA, 5OP, MOVA and a 
combination of MOVA and 5OP-treated mice identifies enhanced glucose uptake of the 
combined treatment in vivo (Representative images from 5 independent repeats). Scale bars 
are standardized uptake value (SUV) in rainbow scale (0 violet – 5 red). Right – CT, middle - 
PET, left – PET/CT co-registration. (e) PET/CT demonstrates that a combined MOVA and 
5OP treatment significantly increases uptake of the glucose analogue 18F-FDG into the 
skeletal muscle of the hind limbs compared with either 5OP or MOVA treatment alone, 
expressed as standardized uptake values g/ml (n = 5; Two-Way ANOVA with Holm-Sidak post 
hoc; Control vs 5OP + MOVA p < 0.0001, BHIBA vs 5OP + MOVA p < 0.0001, 5OP vs 5OP + 
MOVA p < 0.0001, MOVA vs 5OP + MOVA p = 0.0024). Dark green = MOVA, light green = 
5OP, dark blue = BHIBA, red = MOVA + 5OP. ∗p ≤ 0.05, ^p ≤ 0.01, •p ≤ 0.001. Data in bar 




Supplementary Figure 11. MOVA and 5OP signal through cAMP-PKA-p38 MAPK and 
BHIBA via mTOR to regulate adipocyte and myocyte metabolic gene expression  
Cyclic AMP concentrations in the (a) brown adipose tissue (BAT) (5OP p = 0.0024, MOVA p 
= 0.014), (b) inguinal white adipose tissue (WAT) (5OP p = 0.0002, MOVA p = 0.0034)  and 
(c) soleus skeletal muscle (5OP p < 0.0001, MOVA p = 0.011 of mice treated with 100 
mg/Kg/day 3-methyl-2-oxovaleric acid (MOVA), 100 mg/Kg/day 5-oxoproline (5OP) or 125 
mg/Kg/day β-hydroxyisobutyric acid (BHIBA) for 17 weeks (n = 5).  MOVA increased (d) brown 
adipose tissue (BAT) MKK3 (p = 0.0009), p38 MAPKα (p = 0.012) and p38MAPKβ (p = 
0.0057), (e) inguinal white adipose tissue (WAT) p38MAPKβ (p = 0.02) and (f) soleus p38 
MAPKδ (p = 0.0003) and GSK3β (p = 0.0026) phosphorylation in mice (n = 4). 5OP increased 
(g) BAT p38MAPKα (p = 0.0048) and p38MAPKβ (p = 0.0019), and (h) inguinal WAT 
p38MAPKβ (p = 0.0042) and (i) soleus p38MAPKδ (p = 0.00029) and GSK3β (p = 0.00019) 
phosphorylation in mice (n = 4). BHIBA increased phosphorylation of mTOR and p70S6K in 
(j) BAT (mTOR p = 0.0008; p70S6K p = 0.018), (k) inguinal WAT (mTOR p = 0.0003; p70S6K 
p = 0.038) and (l) soleus muscle (mTOR p = 0.003; p70S6K p = 0.002) of mice (n = 4). The 
phospho mTOR / total mTOR ratio in (m) BAT (p = 0.046) and (n) soleus skeletal muscle (p = 
0.03) of 125 mg/Kg/day BHIBA treated mice. Dark green = MOVA, light green = 5OP, dark 
blue = BHIBA. Significance was derived from a two-tailed t-test. ∗p ≤ 0.05, ^p ≤ 0.01, •p ≤ 
0.001, ‡p ≤ 0.0001. Data are mean ± SEM with individual data points shown. Source data are 








α-hydroxyisocaproic acid (HIC) 0.25 ± 0.02 Hoffer et al.1 
α-ketoisovaleric acid (AKV) 
11 ± 1.7  
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3-methyl-2-oxovaleric acid (MOVA) 





Geigy Scientific Tables, 8th Rev 
edition, pp. 165-177. 
 
Hoffmann et al.2 
 
β-hydroxyisobutyric acid (BHIBA) 21.0 +/- 2.0 Avogaro et al3 
β-hydroxyisovaleric acid (BHIVA) ≤10 Engelke et al.4 
5-oxo-proline (5OP) 19.5 ± 3.7 Friesen et al.5 
 




Target Fold-change p-value 
UCP1 20.754 0.06 
LPL 6.61 0.06 
LEP 5.985 0.02 
CKMT2 4.028 0.06 
FASN 3.252 0.03 
NPR1 3.185 0.04 
SLC36A2 3.1 0.06 
ADIPOQ 3.04 0.03 
CEBPA 3.017 0.04 
IL1B 2.755 0.08 
NR1H3 2.622 0.01 
PNPLA2 2.559 0.06 
FABP4 2.311 0.01 
CKMT1B 2.271 0.009 
Perilipin 1 2.199 0.04 
MLXIPL 2.099 0.05 
CPT1B 2.065 0.09 
GATM 2.03 0.07 
SLC27A1 1.908 0.02 
SLC2A4 1.894 0.02 
CD36 1.801 0.03 
PGC1A 1.738 0.01 
SPARC 1.655 0.001 
Adipsin 1.623 0.006 
PRDM16 1.611 0.007 
NPR3 1.539 0.04 
PPARG 1.49 0.05 
INSR 1.436 0.02 
PPARA 1.383 0.03 
SREBF1 1.297 0.06 
BMPR1A 1.286 0.04 
IGF1R 1.258 0.03 
ELOVL6 1.247 0.01 
ATF2 1.234 0.03 
CREB1 1.207 0.05 
NRF1 1.158 0.03 
 
Supplementary Table 2. Table of gene expression array data of key adipocyte and brown 
adipocyte-associated genes changed in immortalized human white preadipocytes isolated 
from neck fat and differentiation to adipocytes in the presence of 3-methyl-2-oxovaleric acid 
(20 μM) (Expression targets ordered by magnitude fold change, p ≤ 0.1; Benjamini Hochberg-
adjusted two-tailed t-tests; n = 3). Source data are provided as a Source Data file. 
Target Fold-change p-value 
UCP1 14.776 0.08 
LEP 5.731 0.02 
CKMT1A/B 4.695 0.05 
CKMT2 4.205 0.05 
NPR1 3.677 0.02 
FABP4 3.468 0.06 
FASN 3.053 0.03 
CEBPA 2.919 0.04 
ADIPOQ 2.793 0.03 
PNPLA2 2.606 0.06 
NR1H3 2.477 0.01 
MLXIPL 2.447 0.03 
Perilipin 1 2.371 0.03 
Adipsin 2.323 0.02 
SLC27A1 2.09 0.02 
CD36 2.054 0.07 
SLC2A4 1.762 0.05 
NPR3 1.629 0.03 
INSR 1.497 0.07 
SPARC 1.486 0.03 
PPARG 1.482 0.05 
SREBF1 1.431 0.003 
NRF1 1.4 0.03 
ELOVL6 1.317 0.02 
ATF2 1.297 0.05 
CREB1 1.295 0.08 
BMPR1A 1.176 0.05 
 
Supplementary Table 3. Table of gene expression array data of key adipocyte and brown 
adipocyte-associated genes changed in immortalized human white preadipocytes isolated 
from neck fat and differentiation to adipocytes in the presence of 5-oxo-proline (20 μM) 
(Expression targets ordered by magnitude fold change, p ≤ 0.1; Benjamini Hochberg-adjusted 
two-tailed t-tests; n = 4). Source data are provided as a Source Data file. 
  
Target Fold change p-value 
LEP 3.484 0.06 
ADRB3 3.327 0.08 
Adipsin 2.204 0.01 
PGC1A 2.019 0.009 
SLC27A1 1.747 0.004 
MLXIPL 1.599 0.08 
INSR 1.58 0.006 
PRDM16 1.546 0.01 
IGF1R 1.493 0.004 
NPR3 1.489 0.04 
NRF1 1.476 0.002 
SPARC 1.473 0.01 
CEBPA 1.455 0.09 
BMPR1A 1.327 0.01 
PPARG 1.324 0.09 
ATF2 1.292 0.01 
TFAM 1.291 0.08 
CREB1 1.258 0.02 
COL6A3 1.191 0.06 
ELOVL6 1.106 0.07 
NRF1 1.077 0.07 
FOXC2 0.753 0.03 
CIDEA 0.119 0.09 
 
Supplementary Table 4. Table of gene expression array data of key adipocyte and brown 
adipocyte-associated genes changed in immortalized human white preadipocytes isolated 
from neck fat and differentiation to adipocytes in the presence of β-hydroxyisobutyric acid (20 
μM) (Expression targets ordered by magnitude fold change, p ≤ 0.1; Benjamini Hochberg-
adjusted two-tailed t-tests; n = 4). Source data are provided as a Source Data file. 
  
Target Fold-change p-value 
UCP1 21.663 0.06 
CKMT1A/B 4.921 0.05 
LPL 4.712 0.09 
CKMT2 3.214 0.09 
FABP4 3.213 0.07 
LEP 2.862 0.09 
SLC36A2 2.655 0.08 
NPR1 2.622 0.07 
IL1B 2.599 0.09 
CEBPA 2.555 0.06 
ADIPOQ 2.438 0.06 
NR1H3 2.392 0.02 
PNPLA2 2.222 0.09 
CD36 2.11 0.06 
FASN 2.085 0.09 
Perilipin 1 1.995 0.05 
MLXIPL 1.954 0.06 
CPT1B 1.917 0.04 
Adipsin 1.884 0.007 
SLC2A4 1.626 0.06 
NPR3 1.596 0.02 
SPARC 1.551 0.002 
PPARG 1.455 0.06 
INSR 1.439 0.002 
BMPR1A 1.407 0.009 
SREBF1 1.294 0.03 
ELOVL6 1.244 0.007 
 
Supplementary Table 5. Table of gene expression array data of key adipocyte and brown 
adipocyte-associated genes changed in immortalized human white preadipocytes isolated 
from neck fat and differentiation to adipocytes in the presence of β-hydroxyisovaleric acid (10 
μM) (Expression targets ordered by magnitude fold change, p ≤ 0.1; Benjamini Hochberg-
adjusted two-tailed t-tests; n = 4). Source data are provided as a Source Data file.
Variant ID Gene SNP ID p-Value Effect Trait Data Set 
6_80866657_T_G BCKDHB rs13220420 0.00000750 -0.0210 BMI GIANT-UK Biobank GWAS Meta-analysis: males 
6_80952806_A_G BCKDHB rs17506768 0.000149 -0.0763 BMI GIANT GWAS: active men 
6_81034583_G_A BCKDHB rs806848 0.000200 -0.00970 BMI GIANT-UK Biobank GWAS Meta-analysis 
6_81035173_A_G BCKDHB rs806845 0.000247 -0.00950 BMI GIANT-UK Biobank GWAS Meta-analysis 
6_81034730_A_G BCKDHB rs806847 0.000262 -0.00950 BMI GIANT-UK Biobank GWAS Meta-analysis 
6_80977740_G_T BCKDHB rs3805901 0.000300 -0.00980 BMI GIANT UK Biobank GWAS 
6_81036745_G_A BCKDHB rs1474790 0.000304 -0.00940 BMI GIANT-UK Biobank GWAS Meta-analysis 
6_81035737_C_A  BCKDHB rs7747016 0.000307 -0.00940 BMI GIANT-UK Biobank GWAS Meta-analysis 
19_49299109_T_C BCAT2 rs73587808 0.000488 0.255 BMI GIANT-UK Biobank GWAS Meta-analysis: females 
12_121167675_G_A ACADS rs12369156 0.000131 -0.0222 BMI GIANT-UK Biobank GWAS Meta-analysis 
12_121179939_C_T ACADS rs12825376 0.000137 0.0138 BMI GIANT-UK Biobank GWAS Meta-analysis: females 
12_121177120_A_G ACADS rs566325901 0.000383 0.167 BMI GIANT-UK Biobank GWAS Meta-analysis 
2_26472711_G_C HADHA  rs559393527 0.0000341 -0.124 BMI GIANT-UK Biobank GWAS Meta-analysis 
2_26472712_A_T HADHA rs529693611 0.0000341 -0.124 BMI GIANT-UK Biobank GWAS Meta-analysis 
2_26472713_A_G HADHA rs548177580 0.0000371 -0.123 BMI GIANT-UK Biobank GWAS Meta-analysis 
2_26472714_T_C HADHA rs563090369 0.0000371 -0.123 BMI GIANT-UK Biobank GWAS Meta-analysis 
 
Supplementary Table 6 Genetic variants in the metabokine biosynthetic genes associated with Body Mass Index in Genome Wide 
Association Study database in Genetic Investigation of ANthropometric Traits (GIANT) and UK Biobank Meta-analysis, including 
795,640 subjects in the Type 2 Diabetes Knowledge Portal (http://www.type2diabetesgenetics.org/). p-value cut-off < 0.0005. 
2_26479414_T_C HADHA rs397984129 0.000461 -0.0873 BMI GIANT-UK Biobank GWAS Meta-analysis 
20_33523155_G_T GSS rs2236270 3.60e-8 0.00980 BMI GIANT UK Biobank GWAS 
20_33525407_G_A GSS rs7265992 8.40e-7 -0.0113 BMI GIANT UK Biobank GWAS 
20_33547633_T_G GSS rs6088662 0.0000250 0.00930 BMI GIANT UK Biobank GWAS 
20_33545055_G_A GSS rs13041792 0.0000260 0.00930 BMI GIANT UK Biobank GWAS 
20_33529766_T_G GSS rs2273684 0.0000280 0.00690 BMI GIANT UK Biobank GWAS 
20_33542605_T_C GSS rs6088659 0.0000285 0.0328 BMI 
GIANT GWAS: men, Europeans, active + inactive 
individuals 
20_33538214_G_A GSS rs35416056 0.0000326 0.0175 BMI GIANT-UK Biobank GWAS Meta-analysis 
20_33522054_T_C GSS rs6087653 0.0000429 0.0250 BMI GIANT GWAS: men, active + inactive individuals 
20_33540000_G_A GSS rs2025096 0.0000580 0.00890 BMI GIANT UK Biobank GWAS 
20_33527838_A_G GSS rs6088655 0.0000679 0.0248 BMI GIANT GWAS: men, active + inactive individuals 
20_33544075_C_G GSS rs3761144 0.0000719 0.0243 BMI GIANT GWAS: men, active + inactive individuals 
7_30544048_C_T GGCT rs549124813 0.0000875 0.174 BMI GIANT-UK Biobank GWAS Meta-analysis: females 








Mean body mass index 
42 74.9 ± 1.3 78.6 84.5 ± 1.3 27.6 ± 0.7 
 
Supplementary Table 7. Morphological parameters for human adipose biopsy volunteers. 
Data shown is Mean ± SEM.   
  
  MOVA 5OP BHIBA BHIVA 
Mouse Primary Adipocytes 
   
 
Secretion during browning ↑ ↑ ↑ ↑ 
Induce brown adipocyte gene expression ↑↑ ↑↑ ↑ ↑ 
     
Human Primary Adipocytes     
Secretion during browning ↑ ↑ ↑ ↑ 
Brown adipocyte gene expression ↑ ↑ ↑ ↑ 
Cellular respiration ↑↑ ↑↑ ↑ ↑ 
UCP1 Protein expression ↑ ↑ ↑ − 
Relative fatty acid oxidation ↑ ↑ ↑↑ − 
Glucose uptake − ↑ ↑ ↑ 
Fatty acid uptake ↑ ↑ ↑ ↑ 
     
Mouse C2C12 Myotubes     
Metabolic gene expression ↑↑ ↑↑ ↑ ↑ 
     
Human Primary Skeletal Myotubes     
Metabolic gene expression ↑↑ ↑↑ ↑ − 
Cellular respiration ↑ ↑ ↑ − 
Glucose uptake ↑ ↑ −  
Fatty acid uptake ↑ ↑ ↑  
     
High Fat Diet-fed C57Bl6 Mice     
Weight gain ↓↓ ↓↓ ↓ − 
Adiposity ↓ ↓ −  
Energy expenditure ↑ ↑ ↑  
Oxygen consumption ↑ ↑ ↑  
Insulin sensitivity ↑ ↑↑ ↑↑ − 
Glucose tolerance − ↑ ↑ − 
BAT Mitochondrial content − ↑ ↑  
Subcutaneous WAT Mitochondrial content − ↑ ↑  
Soleus mitochondrial content ↑ ↑ ↑  
In vivo BAT glucose uptake ↑ − ↑↑  
In vivo hind limb glucose uptake ↑ ↑ ↑  
In vivo fore limb glucose uptake ↑ ↑ −  
 
Supplementary Table 8. Summary of the key metabolic effects of 3-methyl-2-oxovaleric acid 
(MOVA), 5-oxo-proline (5OP), β-hydroxyisobutyric acid (BHIBA) and β-hydroxyisovaleric acid 
(BHIVA) in mouse and human primary adipocytes, mouse and human skeletal myotubes and 
C57Bl6/J mice in vivo. 
 





























































































































































































































FOXC2 Hs00270951_s1 NM_005251.2 102 













































































LEP Hs00174877_m1 NM_000230.2 74 
FGF21 Hs00173927_m1 NM_019113.3 117 


















































SLC2A4 Hs00168966_m1 NM_001042.2 89 






















TNF Hs00174128_m1 NM_000594.3 80 
B2M Hs99999907_m1 NM_004048.2 75 
 
Supplementary Table 9 TaqMan OpenArray Real-Time PCR human primer details giving 
gene, ThermoFisher assay identification number, primer NCBI reference sequence and 
amplicon length. 
  


























PPH02223A-200 911 (NM_021833) 
PGC1α 
(PPARGC1a) 
PPH00461F-200 2303 (NM_013261) 
CIDEA PPH00899C-200 604 (NM_001279) 
CPT1b PPH20905B-200 23 (NM_004377) 
ACADvl PPH01732A-200 1530 (NM_000018) 
CYCS PPH20675F-200 4466 (NM_018947) 
MCT1/SLC16A1 PPH09944F-200 1531 (NM_003051) 
PPARα PPH01281B-200 668 (NM_005036) 










Ucp1 PPM05164B-200 1112 (NM_009463 
Pgc1α 
(Ppargc1α) 
PPM03360I-200 2956 (NM_008904) 
Cidea PPM03423C-200 455 (NM_007702) 
Cpt1b PPM57688A-200 1910 (NM_009948) 
Acadvl PPM04358E-200 1142 (NM_017366) 
Cycs PPM28320A-200 295 (NM_007808) 
Mct1/Slc16a1 PPM25515A-200 1498 (NM_009196) 
Pparα PPM03307C-200 1648 (NM_011144 
Ndufs1 PPM37821A-200 1866 (NM_145518) 
Bcat2 PPM26571A-200 977 (NM_009737) 
Bckdhb PPM25713A-200 0 (NM_199195) 
Acads PPM25953A-200 896 (NM_007383) 
Hadha PPM32964A-200 2221 (NM_178878) 
Gss PPM06172A-200 1323 (NM_008180) 
Ggct PPM38268A-200 532 (NM_026637) 
 
Supplementary Table 10 PCR primer details giving species, gene, commercial vendor, 
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